13 of 100
13. Impax Laboratories
Impax Laboratories

3-year average
Revenue Growth: 43%
Profit Growth: 85%
Total Return: 40%

Of all the companies to make it onto this year's Fastest-Growing list, Impax Labs has likely produced the most volatile results. Over the past five years, net income has fluctuated significantly from as low as $16 million in 2006 and 2008 to as high as $250 million in 2010, and several points in between. The self-described "technology-based speciality pharmaceutical company" specializes in "controlled-release" generic versions of brand-name drugs. Among its biggest sellers are migraine-treating drug Zomig, and Adderall XR, which is used to treat attention deficit disorder. In 2010, net income sky-rocketed 400%. Impax put this down to a one-time accounting benefit, along with increased sales of several key products. Last year profits came crashing down 74%, however, as global sales declined across the board and supply disruptions affected Adderall XR. -- N.S.

Get stock quote: IPXL
Revenue ($ millions): $533
Net Income ($ millions): $64
Sectors: Health Care
From the September 24, 2012 issue.

Northern Oil and Gas 237%
ZAGG 104%
Green Mountain Coffee Roasters 78%
Cirrus Logic 450%
HFF 341%
Questcor Pharmaceuticals 120%
3D Systems 112%
TPC Group 111%
To qualify, a company -- domestic or foreign -- must be trading on a major U.S. stock exchange; file quarterly reports to the SEC; have a minimum market... More